Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDS00125

Target Information
NameOpioid receptor    
Type of targetSuccessful target    
DiseaseAlcoholism    [1]
Analgesics    [1]
Drug dependence    [1]
Eating disorders    [1]
Irritable bowel syndrome    [1]
Pain, unspecified    [1]
NalmefeneApprovedAlcohol dependence[8][9]
Bupropion+naltrexonePhase IIIObesity[13]
Oravescent fentanylPhase IIINeuropathic pain[14]
S-297995Phase IIOpioid induced adverse effect[15]
BioChemical ClassG-protein coupled receptor (rhodopsin family)    
PathwayNeuroactive ligand-receptor interaction
Related US Patent6,395,705
Target ValidationClick to Find Target Validation Information.    
Oravescent fentanyl[14]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. To Reference
Ref 2Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9. To Reference
Ref 3Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22. Epub 2004 Jan 23. To Reference
Ref 4Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25. To Reference
Ref 5mu-Opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Jun 10. [Epub ahead of print] To Reference
Ref 6Differential inhibitory/stimulatory modulation of spinal CCK release by mu and delta opioid agonists, and selective blockade of mu-dependent inhibition by kappa receptor stimulation. Neurosci Lett. 1991 Apr 1;124(2):204-7. To Reference
Ref 7Nat Rev Drug Discov. 2003 Jan;2(1):38-51.Knockouts model the 100 best-selling drugs--will they model the next 100? To Reference
Ref 8Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther. 2009 Feb;328(2):588-97. Epub 2008 Nov 10. To Reference
Ref 9Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008 Jul;32(7):1159-66. To Reference
Ref 10Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8. To Reference
Ref 11Propiram. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use as an analgesic. Drugs. 1993 Sep;46(3):428-45. To Reference
Ref 12Tramadol: basic pharmacology and emerging concepts. Drugs Today (Barc). 2008 Nov;44(11):827-36. To Reference
Ref 13Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. To Reference
Ref 14Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. To Reference
Ref 152011 Pipeline of Shionogi. To Reference
Ref 16Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543